Literature DB >> 7929615

Molecular physiology of amylin.

R A Pittner1, K Albrandt, K Beaumont, L S Gaeta, J E Koda, C X Moore, J Rittenhouse, T J Rink.   

Abstract

Amylin is a 37-amino acid peptide first isolated, purified, and characterized from the amyloid deposits in the pancrease of type 2 diabetics. It is synthesized and secreted primarily from pancreatic beta cells along with insulin. The ability of amylin to potently reduce insulin-stimulated incorporation of glucose into glycogen in skeletal muscle requires both an intact 2Cys-7Cys disulfide bond and a COOH-terminal amide. Amylin has structural and functional relationships to two other messenger proteins, calcitonin and CGRP. Amylin has relatively potent calcitonin-like activity on bone metabolism and weaker CGRP-like activity on the vasculature. CGRP is a slightly weaker agonist than amylin for metabolic responses. Although rat calcitonins are weak, teleost fish calcitonins are very potent agonists for amylin's metabolic effects. This group of peptides appears to act on a family of related G protein-coupled receptors; several variant calcitonin receptors have recently been cloned and expressed. These receptors appear to be coupled to adenylyl cyclase in many instances; recent evidence supports the view that amylin's effects on skeletal muscle occur, at least in large part, through activation of the cAMP pathway.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929615     DOI: 10.1002/jcb.240550004

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  28 in total

1.  Increased alphaCGRP potency and CGRP-receptor antagonist affinity in isolated hypoxic porcine intramyocardial arteries.

Authors:  Philip Hasbak; Karen Eskesen; Søren Schifter; Lars Edvinsson
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

Review 2.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

Review 3.  New advances in models and strategies for developing anti-obesity drugs.

Authors:  Gilbert W Kim; Jieru E Lin; Erik S Blomain; Scott A Waldman
Journal:  Expert Opin Drug Discov       Date:  2013-04-29       Impact factor: 6.098

Review 4.  Peptides and their potential role in the treatment of diabetes and obesity.

Authors:  Hannah C Greenwood; Stephen R Bloom; Kevin G Murphy
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 5.  Neuroendocrine hormone amylin in diabetes.

Authors:  Xiao-Xi Zhang; Yan-Hong Pan; Yan-Mei Huang; Hai-Lu Zhao
Journal:  World J Diabetes       Date:  2016-05-10

Review 6.  Regulation of appetite to treat obesity.

Authors:  Gilbert W Kim; Jieru E Lin; Michael A Valentino; Francheska Colon-Gonzalez; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

7.  High-protein diet selectively reduces fat mass and improves glucose tolerance in Western-type diet-induced obese rats.

Authors:  Andreas Stengel; Miriam Goebel-Stengel; Lixin Wang; Eugenia Hu; Hiroshi Karasawa; Joseph R Pisegna; Yvette Taché
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

8.  A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system.

Authors:  Katrina M Miranda; Nazareno Paolocci; Tatsuo Katori; Douglas D Thomas; Eleonora Ford; Michael D Bartberger; Michael G Espey; David A Kass; Martin Feelisch; Jon M Fukuto; David A Wink
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-15       Impact factor: 11.205

9.  Different pharmacological characteristics in L6 and C2C12 muscle cells and intact rat skeletal muscle for amylin, CGRP and calcitonin.

Authors:  R A Pittner; D Wolfe-Lopez; A A Young; K Beaumont
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

10.  Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes.

Authors:  Gina Ryan; Tim A Briscoe; Lynette Jobe
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.